Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Launched by PEKING UNIVERSITY CANCER HOSPITAL & INSTITUTE · Apr 8, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring new treatment options for patients with unresectable hepatocellular carcinoma (HCC), which is a type of liver cancer that cannot be surgically removed. The study is testing combinations of two different types of treatments: one group will receive Adebrelimab with Apatinib, another group will receive Adebrelimab with Bevacizumab, and the third group will get Camrelizumab with Apatinib. The main goal is to see how effective and safe these combinations are for patients who have not received other treatments for their HCC.

To participate, patients should have advanced liver cancer that cannot be treated with surgery and meet certain health criteria, such as having a specific performance status and adequate organ function. Participants will be monitored closely throughout the trial to assess how well the treatments work and to ensure their safety. This study is currently looking for participants aged 65 and older, regardless of gender. If you or someone you know is interested in participating, this trial could provide access to promising new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)
• • No prior systemic therapy for HCC. Previous use of herbal therapies/traditional Chinese medicines with anti-cancer activity included in the label is allowed.
• • BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy
• • At least one measurable lesion per RECIST v1.1
• • ECOG Performance Status of 0 or 1
• • Child-Pugh class of A5 to B7
• • Adequate organ function
• Exclusion Criteria:
• • Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously
• • Moderate-to-severe ascites with clinical symptoms
• • History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage
• • Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment
• • Known genetic or acquired hemorrhage or thrombotic tendency
• • Thrombosis or thromboembolic event within 6 months prior to the start of study treatment
• • Hypertension that can not be well controlled through antihypertensive drugs Factors to affect oral administration
• • History of hepatic encephalopathy
• • Previous or current presence of metastasis to central nervous system